Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Bayer AG. (7/21/17). "Press Release: Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma [Not intended for U.S. and UK Media]". Berlin.

Organisations Organisation Bayer AG
  Group Bayer (Group)
  Organisation 2 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
  Group MorphoSys (Group)
Products Product anetumab ravtansine (BAY 94-9343)
  Product 2 clinical research
Person Person LaCaze, Robert (Bayer 201702– EVP of new Oncology Strategic Business Unit joined 2015 from BMS)
     


   
Record changed: 2017-07-26

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px